American Chemical SocietyThe pathogen that causes conditions from strep throat to flesh-eating disease is among them, but scientists have now found a tool that could help them fight it: a drug approved to treat HIV. Their work, appearing in the American Chemical Society journal ACS Chemical Biology, could someday lead to new treatments.
Douglas A. Mitchell and colleagues point out that Streptococcus pyogenes is responsible for more than 600 million illnesses and 500,000 deaths globally every year. A major factor in the pathogen's ability to cause disease is its production of a toxin called streptolysin S, or SLS. If scientists could figure out a way to jam the bacterial machinery that makes the compound, they could develop new therapies to fight the pathogen and slow the spread of antibiotic resistance. But not much is known about how S. pyogenes makes SLS. Mitchell's team wanted to start filling in the blanks.
The researchers turned to an HIV drug called nelfinavir. Although the drug's target is an HIV protein, it is also known to incidentally block a key enzyme in patients. That enzyme is related to one in S. pyogenes that is critical for producing SLS. The scientists made several nelfinavir-like compounds that stopped the bacteria from making the toxin in lab tests. They conclude that the drug and its variants could help future efforts to understand how the deadly bacteria works and how to stop it.
The authors acknowledge funding from the National Institutes of Health.
Like this article? Click here to subscribe to free newsletters from Lab Manager